1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > ImmunoGen, Inc. - Product Pipeline Review - 2015

ImmunoGen, Inc. - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 42 pages

ImmunoGen, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘ImmunoGen, Inc. - Product Pipeline Review - 2015’, provides an overview of the ImmunoGen, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ImmunoGen, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of ImmunoGen, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of ImmunoGen, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the ImmunoGen, Inc.’s pipeline products

Reasons to buy

- Evaluate ImmunoGen, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of ImmunoGen, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the ImmunoGen, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of ImmunoGen, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of ImmunoGen, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of ImmunoGen, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

ImmunoGen, Inc. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
ImmunoGen, Inc. Snapshot 5
ImmunoGen, Inc. Overview 5
Key Information 5
Key Facts 5
ImmunoGen, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
ImmunoGen, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
ImmunoGen, Inc. - Pipeline Products Glance 13
ImmunoGen, Inc. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
ImmunoGen, Inc. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
ImmunoGen, Inc. - Drug Profiles 16
coltuximab ravtansine 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
IMGN-529 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
mirvetuximab soravtansine 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
huHER3-8 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
IMGN-289 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
IMGN-779 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
ImmunoGen, Inc. - Pipeline Analysis 25
ImmunoGen, Inc. - Pipeline Products by Target 25
ImmunoGen, Inc. - Pipeline Products by Route of Administration 26
ImmunoGen, Inc. - Pipeline Products by Molecule Type 27
ImmunoGen, Inc. - Pipeline Products by Mechanism of Action 28
ImmunoGen, Inc. - Recent Pipeline Updates 29
ImmunoGen, Inc. - Dormant Projects 34
ImmunoGen, Inc. - Discontinued Pipeline Products 35
Discontinued Pipeline Product Profiles 35
AVE-1642 35
AVE-9633 35
cantuzumab ravtansine 35
coltuximab ravtansine 36
IMGN-388 36
lorvotuzumab mertansine 36
Oncolysin B 36
ImmunoGen, Inc. - Company Statement 37
ImmunoGen, Inc. - Locations And Subsidiaries 40
Head Office 40
Other Locations and Subsidiaries 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

List of Tables
ImmunoGen, Inc., Key Information 5
ImmunoGen, Inc., Key Facts 5
ImmunoGen, Inc. - Pipeline by Indication, 2015 7
ImmunoGen, Inc. - Pipeline by Stage of Development, 2015 9
ImmunoGen, Inc. - Monotherapy Products in Pipeline, 2015 10
ImmunoGen, Inc. - Partnered Products in Pipeline, 2015 11
ImmunoGen, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 12
ImmunoGen, Inc. - Phase II, 2015 13
ImmunoGen, Inc. - Phase I, 2015 14
ImmunoGen, Inc. - Preclinical, 2015 15
ImmunoGen, Inc. - Pipeline by Target, 2015 25
ImmunoGen, Inc. - Pipeline by Route of Administration, 2015 26
ImmunoGen, Inc. - Pipeline by Molecule Type, 2015 27
ImmunoGen, Inc. - Pipeline Products by Mechanism of Action, 2015 28
ImmunoGen, Inc. - Recent Pipeline Updates, 2015 29
ImmunoGen, Inc. - Dormant Developmental Projects,2015 34
ImmunoGen, Inc. - Discontinued Pipeline Products, 2015 35
ImmunoGen, Inc., Subsidiaries 40

List of Figures
ImmunoGen, Inc. - Pipeline by Top 10 Indication, 2015 7
ImmunoGen, Inc. - Pipeline by Stage of Development, 2015 9
ImmunoGen, Inc. - Monotherapy Products in Pipeline, 2015 10
ImmunoGen, Inc. - Partnered Products in Pipeline, 2015 11
ImmunoGen, Inc. - Pipeline by Top 10 Target, 2015 25
ImmunoGen, Inc. - Pipeline by Top 10 Route of Administration, 2015 26
ImmunoGen, Inc. - Pipeline by Top 10 Molecule Type, 2015 27
ImmunoGen, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 28

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016’, ...

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Pipeline Review, H2 2016

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • November 2016
  • by Global Markets Direct

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) ...

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Pipeline Review, H2 20

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Pipeline Review, H2 20

  • $ 3500
  • Company report
  • November 2016
  • by Global Markets Direct

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B o ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.